<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543929</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00143513</org_study_id>
    <nct_id>NCT04543929</nct_id>
  </id_info>
  <brief_title>Effects of Innovative Aerobic Exercise Training in Cystic Fibrosis</brief_title>
  <official_title>Effects of Innovative Aerobic Exercise Training in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized controlled trial in patients with cystic fibrosis and&#xD;
      conducted over a consecutive twelve-week period. A comparison standard of care group will be&#xD;
      used as a control to an interventional exercise group. The study evaluates the effectiveness&#xD;
      of standard of care therapy + exercise compared to standard of care only for improving&#xD;
      cardiorespiratory-fitness in CF patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aerobic Exercise Capacity</measure>
    <time_frame>3 months</time_frame>
    <description>anaerobic threshold via Sub-maximal cardiopulmonary exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary function</measure>
    <time_frame>3 months</time_frame>
    <description>forced expiratory volume in 1 second (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured by CFQ-R</measure>
    <time_frame>3 months</time_frame>
    <description>cystic fibrosis questionnaire (CFQ-R) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on sweat chloride</measure>
    <time_frame>3 months</time_frame>
    <description>Sweat Chloride Testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetes risk</measure>
    <time_frame>3 months</time_frame>
    <description>Point-of-Care HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>exercise prescription + standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no exercise</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no exercise prescription + standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise</intervention_name>
    <description>partially supervised and home-based exercise activity</description>
    <arm_group_label>exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed with Cystic Fibrosis&#xD;
&#xD;
          -  Prescribed and taking for 28 days ivacaftor-tezacaftor-elexacaftor (Trikafta)&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  17 years of age or less&#xD;
&#xD;
          -  not eligible for ivacaftor-tezacaftor-elexacaftor (Trikafta)&#xD;
&#xD;
          -  inability to exercise&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  status post lung transplantation&#xD;
&#xD;
          -  already participating in more than 150 minutes of aerobic exercise per week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Burnett, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine D Morgan, BA</last_name>
    <phone>913-588-1572</phone>
    <email>cmorgan6@kumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Larry Scott</last_name>
    <phone>913-588-1572</phone>
    <email>lscott2@kumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Morgan</last_name>
      <phone>913-588-1572</phone>
      <email>cmorgan6@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Larry Scott</last_name>
      <phone>913-588-1572</phone>
      <email>lscott2@kumc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Dave Burnett</investigator_full_name>
    <investigator_title>Ph.D., Chair Dept. of Respiratory Care and Diagnostic Science</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

